The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Strata Critical Medical Inc (NASDAQ: SRTA) closed at $4.19 in the last session, down -3.46% from day before closing price of $4.34. In other words, the price has decreased by -$3.46 from its previous closing price. On the day, 1.03 million shares were traded. SRTA stock price reached its highest trading level at $4.345 during the session, while it also had its lowest trading level at $4.17.
Ratios:
We take a closer look at SRTA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.39 and its Current Ratio is at 4.39. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, Lake Street on February 26, 2025, initiated with a Buy rating and assigned the stock a target price of $6.50. On July 18, 2023, Ladenburg Thalmann started tracking the stock assigning a Buy rating and target price of $13. On July 17, 2023, Ladenburg Thalmann started tracking the stock assigning a Buy rating and target price of $13.Ladenburg Thalmann initiated its Buy rating on July 17, 2023, with a $13 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 20 ’25 when Love Reginald sold 11,000 shares for $4.37 per share. The transaction valued at 48,070 led to the insider holds 113,897 shares of the business.
Love Reginald sold 11,000 shares of SRTA for $47,434 on Nov 19 ’25. The Director now owns 124,897 shares after completing the transaction at $4.31 per share. On Nov 20 ’25, another insider, Reginald Lamonte Love, who serves as the Director of the company, bought 11,000 shares for $4.37 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SRTA now has a Market Capitalization of 361875744 and an Enterprise Value of 15248575. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.58 while its Price-to-Book (P/B) ratio in mrq is 1.27. Its current Enterprise Value per Revenue stands at 0.227 whereas that against EBITDA is -0.495.
Stock Price History:
The Beta on a monthly basis for SRTA is 1.99, which has changed by 0.014018655 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, SRTA has reached a high of $6.02, while it has fallen to a 52-week low of $2.35. The 50-Day Moving Average of the stock is -14.42%, while the 200-Day Moving Average is calculated to be 5.82%.
Shares Statistics:
According to the various share statistics, SRTA traded on average about 883.90K shares per day over the past 3-months and 1068990 shares per day over the past 10 days. A total of 86.05M shares are outstanding, with a floating share count of 60.87M. Insiders hold about 29.52% of the company’s shares, while institutions hold 52.81% stake in the company. Shares short for SRTA as of 1763078400 were 3999733 with a Short Ratio of 4.53, compared to 1760486400 on 2386125. Therefore, it implies a Short% of Shares Outstanding of 3999733 and a Short% of Float of 6.859999999999999.
Earnings Estimates
Currently, 1.0 analysts are dedicated to thoroughly evaluating and rating the performance of Strata Critical Medical Inc (SRTA) in the stock market.
Analysts are recommending an EPS of between -$0.15 and -$0.15 for the fiscal current year, implying an average EPS of -$0.15. EPS for the following year is $0.08, with 1.0 analysts recommending between $0.08 and $0.08.
Revenue Estimates
According to 1 analysts,. The current quarter’s revenue is expected to be $60M. It ranges from a high estimate of $60M to a low estimate of $60M. As of. The current estimate, Strata Critical Medical Inc’s year-ago sales were $54.36M
A total of 1 analysts have provided revenue estimates for SRTA’s current fiscal year. The highest revenue estimate was $190.4M, while the lowest revenue estimate was $190.4M, resulting in an average revenue estimate of $190.4M. In the same quarter a year ago, actual revenue was $248.69MBased on 1 analysts’ estimates, the company’s revenue will be $270M in the next fiscal year. The high estimate is $270M and the low estimate is $270M.
